Apogee Therapeutics Reports Positive Phase 1b Data for Zumilokibart in Asthma, Plans Phase 3 Trial in 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 06 2026
0mins
Source: NASDAQ.COM
- Clinical Trial Progress: Apogee Therapeutics reported rapid and durable suppression of fractional exhaled nitric oxide in all patients during the Phase 1b trial of zumilokibart, with effects maintained through 32 weeks in some, indicating strong potential for treating mild-to-moderate asthma.
- Future Data Releases: The company expects to release Phase 2 APEX Part A maintenance data in Q1 2026, followed by induction data from Part B in Q2 2026, which will provide critical insights for further drug development.
- New Trial Plans: Apogee plans to initiate a Phase 3 trial for atopic dermatitis in the second half of 2026, aiming for a potential launch in 2029, demonstrating the company's intent to expand into dermatological treatments, which could open new revenue streams.
- Strong Financial Position: As of September 30, 2025, Apogee had $913 million in cash reserves, ensuring a runway into the second half of 2028, providing robust support for future R&D and market initiatives.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like APGE with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on APGE
Wall Street analysts forecast APGE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for APGE is 102.50 USD with a low forecast of 70.00 USD and a high forecast of 137.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Analyst Rating
13 Buy
1 Hold
0 Sell
Strong Buy
Current: 70.690
Low
70.00
Averages
102.50
High
137.00
Current: 70.690
Low
70.00
Averages
102.50
High
137.00
About APGE
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is advancing novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. APG777, the Company’s most advanced program, is being initially developed for the treatment of AD. With four validated targets in its portfolio, it is seeking to achieve efficacy and dosing through monotherapies and combinations of its novel antibodies. Its most advanced programs are APG777, APG990, APG333, and APG808. APG990 is an SQ extended half-life mAb that utilizes advanced antibody engineering to target OX40L. APG333 is a fully human mAb against thymic stromal lymphopoietin (TSLP). APG808 is an SQ extended half-life mAb targeting IL-4Rα. APG279 is for the dual inhibition of OX40L and IL-13.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Apogee Therapeutics (APGE) Options Volume Surges 46.6% Today
- Active Options Trading: Apogee Therapeutics has seen an options volume of 4,166 contracts today, equating to approximately 416,600 shares, indicating a trading activity level of 46.6% of its average daily volume over the past month.
- High Demand Options: Notably, the $90 strike call option expiring on March 20, 2026, has seen a significant volume of 2,505 contracts traded today, representing about 250,500 shares, reflecting strong market interest at this strike price.
- Ceva Inc Options Activity: Concurrently, Ceva Inc has recorded an options volume of 1,294 contracts today, approximately 129,400 shares, which corresponds to 45.8% of its average daily trading volume over the past month.
- Increased Interest in Strike Price: Among Ceva's options, the $30 strike call option expiring on February 20, 2026, has seen a trading volume of 506 contracts today, representing around 50,600 shares, indicating a rising market focus on this strike price.
Continue Reading
Stocks to Consider Buying in 2026: Insights from Our Roundtable Experts, Including DoorDash and LVMH
Stock Picks Overview: The second installment of the 2026 Barron’s Roundtable features 30 stock picks from five investment experts, highlighting both well-known companies and lesser-known options.
Familiar Names Included: Among the stock picks are recognizable brands such as Home Depot, Starbucks, and Nike, indicating a mix of established and emerging investment opportunities.
Biodegradable Innovation: The article hints at a British company that has recently acquired a manufacturer of biodegradable sneaker midsoles, showcasing a trend towards sustainable products in the footwear industry.
Investment Insights: The Roundtable serves as a platform for sharing diverse investment strategies and insights, appealing to both seasoned investors and those looking to explore new market trends.
Continue Reading